Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials

BACKGROUND: Treatment de-escalation in early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) has been attempted in order to decrease costs and toxicities. One of the strategies pursued is decreasing trastuzumab treatment duration, with mixed results thus far. Trast...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ESMO Open
Hlavní autoři: Eiger, Daniel, Franzoi, Maria Alice, Pondé, Noam, Brandão, Mariana, de Angelis, Claudia, Schmitt Nogueira, Melanie, de Hemptinne, Quentin, de Azambuja, Evandro
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7046387/
https://ncbi.nlm.nih.gov/pubmed/32079624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000659
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky